HUMA
Humacyte, Inc.
There isn't enough reported data to score HUMA yet.
HUMA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Under pressure | |
| Unavailable |
HUMA's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
HUMA PE Valuation
HUMA has no meaningful PE right now: it lost money over the past year.
HUMA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect HUMA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HUMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.50 | -$0.27 |
| Q2 2026 | -$0.55 | -$0.10 |
| Q1 2026 | -$0.63 | +$0.06 |
| Q4 2025 | -$0.26 | +$1.00 |
| Q3 2025 | -$0.23 | +$1.11 |
| Q2 2025 | -$0.45 | +$0.81 |
| Q1 2025 | -$0.69 | +$0.31 |
| Q4 2024 | -$1.26 | -$0.19 |
HUMA is still losing money, but far less than before: $0.50 per share over the past year, against $1.34 at its worst in late 2024.
HUMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1M | +37% |
| Q2 2026 | $406K | +35% |
| Q1 2026 | $495K | -4.3% |
HUMA's revenue is growing: $1M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2288% | +951 points |
| Q2 2026 | -6649% | +3227 points |
| Q1 2026 | -5845% | -1361 points |
| Q4 2025 | -6603% | N/A |
| Q3 2025 | -3239% | N/A |
| Q2 2025 | -9876% | N/A |
| Q1 2025 | -4484% | N/A |
| Q4 2020 | -12639% | N/A |
HUMA's operating margin was −2288% last quarter, up 951 points from the same quarter a year ago, near the top of its range since 2020.
HUMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15M | +$9M |
| Q2 2026 | -$22.2M | +$4.8M |
| Q1 2026 | -$25.3M | +$3.6M |
| Q4 2025 | -$26.2M | +$477K |
| Q3 2025 | -$24M | -$112K |
| Q2 2025 | -$27M | -$5.5M |
| Q1 2025 | -$28.8M | -$1.1M |
| Q4 2024 | -$26.6M | -$7.4M |
HUMA has burned cash in almost every quarter: −$89M over the past year, against −$106M the year before.
HUMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +19% | +43.6M shares |
| 1 year | +79% | +122M shares |
| 3 years | +169% | +175M shares |
HUMA has 278M diluted shares, up 79% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HUMA Net Leverage
HUMA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HUMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.2 | Neutral |
| Stochastic | 35.8 | Neutral |
HUMA's weekly RSI is 46 (neutral) and its Stochastic is 36 (neutral).
HUMA PE vs Healthcare Sector
HUMA has no meaningful PE right now: it lost money over the past year.
HUMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.48 | 25% above |
| 20 week MA | $0.58 | 3.4% above |
| 50 week MA | $0.83 | 28% below |
| 100 week MA | $1.66 | 64% below |
| 200 week MA | $2.86 | 79% below |
HUMA has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 79% below its 200-week average.
HUMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.81 | $9.99 | +1.8% |
| 2021 | $9.99 | $7.76 | -22% |
| 2022 | $7.76 | $2.30 | -70% |
| 2023 | $2.30 | $2.84 | +23% |
| 2024 | $2.84 | $5.50 | +94% |
| 2025 | $5.50 | $1.07 | -81% |
| 2026 YTD | $1.07 | $0.60 | -44% |
HUMA has finished lower in three of the last six years. It's down 44% so far in 2026.